Loading...
Summit Therapeutics Inc.
SMMT•NASDAQ
HealthcareBiotechnology
$20.59
$0.86(4.36%)
Summit Therapeutics Inc. (SMMT) Financial Performance & Statements
Review Summit Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
100.35%
↑ 100.35%
Net Income Growth
64.010%
↑ 64.010%
Operating Cash Flow Growth
-85.13%
↓ 85.13%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-70.50%
↓ 70.50%
ROIC
-48.29%
↓ 48.29%
Summit Therapeutics Inc. (SMMT) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Summit Therapeutics Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $19999.00 | $20000.00 | $27000.00 |
| Gross Profit | $0.00 | -$19999.00 | -$20000.00 | -$27000.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $66.39M | $37.72M | $30.80M | $30.87M |
| SG&A Expenses | $14.41M | $20.39M | $13.95M | $11.73M |
| Operating Expenses | $65.61M | $58.38M | $44.75M | $42.39M |
| Total Costs & Expenses | $65.61M | $58.11M | $44.77M | $42.39M |
| Interest Income | $13.47M | $0.00 | $0.00 | $0.00 |
| Interest Expense | $9000.00 | $2.46M | $3.10M | $3.12M |
| Depreciation & Amortization | $22000.00 | $20000.00 | $20000.00 | $27000.00 |
| EBITDA | -$61.38M | -$53.52M | -$57.42M | -$40.54M |
| EBITDA Ratio | ||||
| Operating Income | -$65.61M | -$58.11M | -$44.77M | -$42.39M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $4.44M | $1.86M | -$15.78M | -$1.08M |
| Income Before Tax | -$61.18M | -$56.25M | -$60.54M | -$43.47M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | -$159000.00 | $3.12M |
| Net Income | -$61.20M | -$56.25M | -$60.38M | -$43.47M |
| Net Income Ratio | ||||
| EPS | -$0.08 | -$0.08 | -$0.09 | -$0.06 |
| Diluted EPS | -$0.08 | -$0.08 | -$0.09 | -$0.06 |
| Weighted Avg Shares Outstanding | $737.50M | $726.66M | $707.90M | $701.79M |
| Weighted Avg Shares Outstanding (Diluted) | $737.50M | $726.66M | $707.90M | $701.79M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan